Natera Inc.
(NASDAQ:NTRA) stock surged Friday after the genetic testing company reported second-quarter results that topped Wall Street estimates and raised its full-year revenue outlook, supported by strong oncology demand and continued momentum across its Women's Health and Organ Health businesses.
The company reported a second-quarter loss of 47 cents per share, beating the consensus estimate for a loss of 51 cents per share.
Revenue increased 37.7% year over year to $752.8 million, exceeding the analyst consensus estimate of $660.7 million.
The growth was driven by higher test volumes and improved average selling prices.
